2018-06-06T14:57:04-04:00 2017-12-31 521373858 DELEON & STANG CPAS AND ADVISORS 100 LAKEFOREST BLVD STE 650 GAITHERSBURG MD 208772609 990 2017-01-01 202897110 BLADDER CANCER ADVOCACY NETWORK INC BLAD 3012159099 4915 ST ELMO AVENUE BETHESDA MD 20814 ANDREA MADDOX-SMITH CEO 3012159099 2018-06-01 true CLINT LEHMAN CPA P00840525 3019489825 2018-06-06 2017 2022-09-23 18:48:47Z ANDREA MADDOX-SMITH 4915 ST ELMO AVE NO 202 BETHESDA MD 20814 2922318 false X WWW.BCAN.ORG X 2005 MD TO INCREASE PUBLIC AWARENESS ABOUT BLADDER CANCER, TO ADVANCE BLADDER CANCER RESEARCH, AND TO PROVIDE EDUCATIONAL AND SUPPORT SERVICES FOR THE BLADDER CANCER COMMUNITY. 12 12 7 0 2459875 2727002 89937 181120 403 12094 980 2102 2551195 2922318 464512 542768 0 570727 630556 0 158096 753594 930978 1788833 2104302 762362 818016 3477531 4442850 170109 317412 3307422 4125438 X TO INCREASE PUBLIC AWARENESS ABOUT BLADDER CANCER, TO ADVANCE BLADDER CANCER RESEARCH, AND TO PROVIDE EDUCATIONAL AND SUPPORT SERVICES FOR THE BLADDER CANCER COMMUNITY. false false 642299 542768 RESEARCH - BCAN WORKS TO ADVANCE BLADDER CANCER RESEARCH. RECOGNIZING THE OVERWHELMING NEED FOR RESEARCH FUNDING, BCAN HAS ENGAGED A NEW GENERATION OF RESEARCHERS WITH THE YOUNG INVESTIGATOR RESEARCH AWARDS, AND IN 2017 GRANTED TWO AWARDS. IN ADDITION, BCAN SUPPORTS EXCEPTIONALLY NOVEL AND CREATIVE PROJECTS WITH GREAT POTENTIAL TO PRODUCE BREAKTHROUGHS IN THE MANAGEMENT OF BLADDER CANCER THROUGH ITS BLADDER CANCER RESEARCH INNOVATION AWARD, A 300,000 GRANT AWARDED OVER TWO-YEARS. ONE RESEARCH INNOVATION AWARD WAS GRANTED IN 2017. TO ENCOURAGE GREATER COLLABORATION AMONG BLADDER CANCER RESEARCHERS, BCAN LAUNCHED THE BLADDER CANCER GENOMICS CONSORTIUM (BCGC), A COLLABORATIVE EFFORT BETWEEN BCAN AND MAJOR MEDICAL CENTERS, WITH THE GOAL OF DEVELOPING AN ENRICHED UNDERSTANDING OF THE GENOMIC PROFILE OF BLADDER CANCER TO FACILITATE THE DEVELOPMENT OF NOVEL THERAPEUTICS. THE FIRST RESEARCH PROJECT IS UNDERWAY WHICH FOCUSES ON PATIENTS WITH METASTATIC DISEASE, AN AREA IN GREAT NEED OF IMPROVED TREATMENTS. BCAN HAS INVESTED 2.3 MILLION FROM PRIVATE PHILANTHROPY TO SUPPORT THE STUDY MANAGEMENT, SUPPORT SERVICES, AND GENOMIC SEQUENCING REPORTING - COSTS WHICH ARE OFTEN A BARRIER TO PERSONALIZED CARE FOR PATIENTS. WITH THE LAUNCH OF BCGC, BCAN HAS NOW INVESTED MORE THAN 3 MILLION IN BLADDER CANCER RESEARCH. 290141 EDUCATION AND INFORMATION - BCAN HOSTS A VARIETY OF EDUCATIONAL PROGRAMS AND PUBLISHES PRINTED MATERIALS TO EDUCATE THOSE COPING WITH A BLADDER CANCER DIAGNOSIS. NOW IN ITS SECOND PRINTING, BCAN'S COMPREHENSIVE PATIENT HANDBOOK, "BLADDER CANCER BASICS FOR THE NEWLY DIAGNOSED," HAS BEEN PROVIDED TO THOUSANDS OF SURVIVORS, CAREGIVERS, UROLOGY PRACTICES, AND CANCER CENTERS ACROSS THE UNITED STATES. THE PATIENT INSIGHT WEBINAR SERIES IS AN INTERACTIVE WEB PROGRAM THAT ADDRESSES A VARIETY OF ISSUES FROM CLINICAL TRIALS TO LIVING WITH URINARY DIVERSION. THE WEBINARS FEATURE TOP EXPERTS IN THEIR FIELD AND ADDRESS PATIENT CONCERNS IN AN EASY FORMAT. BCAN CONNECTION, AN INFORMATION AND REFERRAL LINE PROVIDING PRACTICAL RESOURCES FOR THOSE COPING WITH A BLADDER CANCER DIAGNOSIS IS STAFFED BY COMMUNITY VOLUNTEERS. THE SURVIVOR 2 SURVIVOR PROGRAM CONNECTS NEWLY DIAGNOSED PATIENTS WITH SURVIVORS WITH A SIMILAR DIAGNOSIS. 317696 THINK TANK - THE BLADDER CANCER THINK TANK (THINK TANK) IS THE ONLY MEDICAL SYMPOSIUM DEDICATED SOLELY TO BLADDER CANCER. THROUGH COLLABORATION UROLOGISTS, ONCOLOGISTS, SCIENTISTS, AND RESEARCHERS ARE PIONEERING NEW TREATMENT PROTOCOLS, INVESTIGATING GENETIC EXPRESSIONS, AND IMPROVING ACCESS TO QUALITY CARE FOR THOSE LIVING WITH THE DISEASE. THE JOHN QUALE TRAVEL FELLOWSHIP PROGRAM PROVIDES FINANCIAL SUPPORT TO HELP SELECT RESEARCHERS PAY TRAVEL EXPENSES RELATED TO THEIR ATTENDANCE AT THE ANNUAL BLADDER CANCER THINK TANK WHERE THEY HAVE THE OPPORTUNITY TO PRESENT THEIR RESEARCH, NETWORK WITH LEADING BLADDER CANCER RESEARCHERS AND GAIN INSIGHTS FROM THE THINK TANK. EACH YEAR, FOUR 1,700 TRAVEL FELLOWSHIPS ARE AWARDED TO EARLY CAREER PHYSICIANS AND SCIENTISTS. THE 2017 THINK TANK IN DENVER, CO, WAS THE LARGEST TO DATE ENGAGING OVER 230 PARTICIPANTS. 309851 WALK FOR BLADDER CANCER - THE WALK FOR BLADDER CANCER IS AN AWARENESS INITIATIVE IN MAY THAT UNITES BLADDER CANCER SURVIVORS, LOVED ONES, AND THE MEDICAL COMMUNITY TO PROMOTE RECOGNITION AND UNDERSTANDING OF THE DISEASE. IN 2017, THIS COMMUNITY EVENT WAS IN OVER 30 COMMUNITIES WITH 250 TEAMS PARTICIPATING ACROSS THE COUNTRY. NATION IN SCOPE, THE WALK TO END BLADDER CANCER REACHED MORE THAN 600,000 THROUGH THE WALK AWARENESS CAMPAIGN. THE EVENT INCLUDES A HEALTH WALK, SURVIVOR RECOGNITION AND EDUCATION ABOUT THE SIGNS AND SYMPTOMS OF BALDDER CANCER. MANY WALK PARTICIPANTS ALSO RAISE FUNDS TO SUPPORT BCAN'S MISSION PROGRAMS. THE WALK FOR BLADDER CANCER IS HELD IN MAY AS PART OF BLADDER CANCER AWARENESS MONTH. ADVOCACY - AS THE VOICE FOR THE PATIENT COMMUNITY, BCAN PARTICIPATES IN COALITIONS AND WORKS WITH OTHER MEMBERSHIP GROUPS TO WEIGH IN ON POLICY ISSUES THAT DIRECTLY IMPACT THOSE LIVING WITH BLADDER CANCER. IN 2016, BCAN HOSTED AN ADVOCACY DAY ON CAPITOL HILL FOR SURVIVORS AND LOVED ONES TO MEET WITH THEIR CONGRESSIONAL REPRESENTATIVES. IN 2017, IN LIEU OF HILL DAY, THE LEADERSHIP SUMMIT FOCUSED ON ADVOCACY ISSUES. ADVOCACY ALERTS WERE DISSEMINATED TO SUPPORT CDMRP RESEARCH FUNDING FOR BLADDER CANCER. 309851 1559987 true true false true false false false false false false true false false false true true true false false false false false false false false false false false true true false false false false false false false false false false false false false false false false false true 7 0 true 7 true false false false false false false false false false false X 12 12 false false false false false false false true true false true true true true true true true true true true false MD IL CA CT FL MA MI MO NJ NY OH PA RI VA WA GA X X X ANDREA MADDOX-SMITH 3012159099 4915 ST ELMO AVE NO 202 BETHESDA MD 20814 GERALD MCNAMARA CHAIRMAN 2.00 X X 0 0 0 DIANE ZIPURSKY QUALE CO-FOUNDER 2.00 X X 0 0 0 ROBERT LEVIN DIRECTOR/TRE 2.00 X X 0 0 0 JARED SHER DIRECTOR/SEC 2.00 X X 0 0 0 MARY GUSHEE DIRECTOR 2.00 X 0 0 0 BEVERLY JAMES DIRECTOR 2.00 X 0 0 0 CHERYL TAYLORE LEE DIRECTOR 2.00 X 0 0 0 SETH LERNER DIRECTOR 2.00 X 0 0 0 DAVID PULVER DIRECTOR 2.00 X 0 0 0 WILLIAM SHIPLEY DIRECTOR 2.00 X 0 0 0 NEAL SHORE DIRECTOR 2.00 X 0 0 0 MACE ROSENTEIN DIRECTOR 2.00 X 0 0 0 ANDREA MADDOX-SMITH CEO 40.00 X 216400 0 0 216400 1 false true false 2727002 2727002 CONFERENCE INCOME 181120 181120 181120 12094 12094 OTHER REVENUE 900099 2102 2102 2102 2922318 183222 12094 542768 542768 216400 140660 38694 37046 347606 227521 62154 57931 30975 20118 5666 5191 35575 23168 6389 6018 27943 18129 5109 4705 105085 83903 21182 83447 34015 49432 118405 83607 21253 13545 86157 10689 73948 1520 73638 47782 13454 12402 85545 56691 28235 619 210177 191932 17889 356 500 325 91 84 7448 4833 1361 1254 MEDIA PRODUCTION SERVICES 40096 40096 PCORI AWARDS 30641 13463 17178 DUES AND MEMBERSHIP 14204 12049 2155 EQUIPMENT RENTAL & MAINT. 12506 8232 2224 2050 35186 12055 9911 13220 2104302 1559987 386219 158096 2244760 3262621 273850 288660 940623 871374 13950 16347 30467 30467 500 3848 3848 3477531 4442850 7288 58525 150000 150000 96110 12821 12777 170109 317412 X 1744232 2483056 1563190 1642382 3307422 4125438 3477531 4442850 818016 X false true X true false X 1022404 1796181 3407347 2459875 2727002 11412809 1022404 1796181 3407347 2459875 2727002 11412809 964512 10448297 263 251 403 917 11094 11094 11424820 183222 0.91450 0.85740 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false true 40935 false false 40935 false SCHEDULE C, PART II-B, LINE 1 THE LOBBYIST COORDINATED THE MEETINGS AND MESSAGING FOR OUR ANNUAL HILL DAY TO SUPPORT BLADDER CANCER AWARENESS MONTH. HE LED A TRAINING FOR OUR PATIENT ADVOCATES WHO JOINED US FROM AROUND THE COUNTRY FOR THIS DAY ON THE HILL. THE LOBBYIST ALSO MET WITH LEGISLATIVE AIDES IN CONGRESSIONAL OFFICES TO URGE THEM TO SUPPORT A RESOLUTION TO RECOGNIZE MAY AS NATIONAL 30467 30467 DEFERRED LEASE BENEFIT 12777 12777 X 2922318 2922318 2922318 2104302 2104302 2104302 SCHEDULE D, PAGE 3, PART X IN GENERAL, WHEN TAX RETURNS ARE FILED, IT IS HIGHLY CERTAIN THAT SOME POSITIONS TAKEN WOULD BE SUSTAINED UPON EXAMINATION BY THE TAXING AUTHORITIES, WHILE OTHERS ARE SUBJECT TO UNCERTAINTY ABOUT THE MERITS OF THE POSITION TAKEN OR THE AMOUNT OF THE POSITION THAT WOULD BE ULTIMATELY SUSTAINED. THE BENEFIT OF THE TAX POSITION IS RECOGNIZED IN THE FINANCIAL STATEMENTS IN THE PERIOD DURING WHICH, BASED ON ALL AVAILABLE EVIDENCE, MANAGEMENT BELIEVES IT IS MORE LIKELY THAN NOT THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION, INCLUDING THE RESOLUTION OF APPEALS OR LTIGATION PROCESSES, IF ANY. TAX POSITIONS TAKEN ARE NOT OFFSET OR AGGREGATED WITH OTHER POSITIONS. TAX POSITIONS THAT MEET THE MORE-LIKELY- THAN-NOT RECOGNITION THRESHOLD ARE MEASURED AS THE LARGEST AMOUNT OF TAX BENEFIT THAT IS MORE THAN 50 PERCENT LIKELY OF BEIGN REALIZED UPON SETTLEMENT WITH THE APPLICABLE TAXING AUTHORITY. THE PORTION OF THE BENEFITS ASSOCIATED WITH TAX POSITIONS TAKEN THAT EXCEEDS THE AMOUNT MEASURED AS DESCRIBED ABOVE IS REFLECTED AS A LIABILITY FOR UNRECOGNIZED TAX BENEFITS IN THE ACCOMPANYING BALANCE SHEETS, ALONG WITH ANY ASSOCIATED INTEREST AND PENALTIES THAT WOULD BE PAYABLE TO THE TAXING AUTHORITIES UPON EXAMINATION. BCAN HAS DETERMINED THAT NO SUCH LIABILITES WERE REQUIRED AT DECEMBER 31, 2017 AND 2016. false RESEARCH 4 542768 SCHEDULE I, PAGE 1, PART I, LINE 2 FOR A 24 MONTH GRANT PERIOD: THE RECIPIENTS ARE REQUIRED TO SUBMIT AN ANNUAL WRITTEN SUMMARIES TO BCAN DOCUMENTING THE PROGRESS MADE IN CONNECTION WITH THE GRANT. false false false false false false false false false ANDREA MADDOX-SMITH CEO 216400 216400 FORM 990, PAGE 2, PART III, LINE 4A GENOMIC PROFILE OF BLADDER CANCER TO FACILITATE THE DEVELOPMENT OF NOVEL THERAPEUTICS. THE FIRST RESEARCH PROJECT IS UNDERWAY WHICH FOCUSES ON PATIENTS WITH METASTATIC DISEASE, AN AREA IN GREAT NEED OF IMPROVED TREATMENTS. BCAN HAS INVESTED 2.3 MILLION FROM PRIVATE PHILANTHROPY TO SUPPORT THE STUDY MANAGEMENT, SUPPORT SERVICES, AND GENOMIC SEQUENCING REPORTING - COSTS WHICH ARE OFTEN A BARRIER TO PERSONALIZED CARE FOR PATIENTS. WITH THE LAUNCH OF BCGC, BCAN HAS NOW INVESTED MORE THAN 3 MILLION IN BLADDER CANCER RESEARCH. FORM 990, PAGE 2, PART III, LINE 4B VOLUNTEERS. THE SURVIVOR 2 SURVIVOR PROGRAM CONNECTS NEWLY DIAGNOSED PATIENTS WITH SURVIVORS WITH A SIMILAR DIAGNOSIS. FORM 990, PAGE 2, PART III, LINE 4C CO, WAS THE LARGEST TO DATE ENGAGING OVER 230 PARTICIPANTS. FORM 990, PAGE 2, PART III, LINE 4D WALK FOR BLADDER CANCER - THE WALK FOR BLADDER CANCER IS AN AWARENESS INITIATIVE IN MAY THAT UNITES BLADDER CANCER SURVIVORS, LOVED ONES, AND THE MEDICAL COMMUNITY TO PROMOTE RECOGNITION AND UNDERSTANDING OF THE DISEASE. IN 2017, THIS COMMUNITY EVENT WAS IN OVER 30 COMMUNITIES WITH 250 TEAMS PARTICIPATING ACROSS THE COUNTRY. NATION IN SCOPE, THE WALK TO END BLADDER CANCER REACHED MORE THAN 600,000 THROUGH THE WALK AWARENESS CAMPAIGN. THE EVENT INCLUDES A HEALTH WALK, SURVIVOR RECOGNITION AND EDUCATION ABOUT THE SIGNS AND SYMPTOMS OF BALDDER CANCER. MANY WALK PARTICIPANTS ALSO RAISE FUNDS TO SUPPORT BCAN'S MISSION PROGRAMS. THE WALK FOR BLADDER CANCER IS HELD IN MAY AS PART OF BLADDER CANCER AWARENESS MONTH. ADVOCACY - AS THE VOICE FOR THE PATIENT COMMUNITY, BCAN PARTICIPATES IN COALITIONS AND WORKS WITH OTHER MEMBERSHIP GROUPS TO WEIGH IN ON POLICY ISSUES THAT DIRECTLY IMPACT THOSE LIVING WITH BLADDER CANCER. IN 2016, BCAN HOSTED AN ADVOCACY DAY ON CAPITOL HILL FOR SURVIVORS AND LOVED ONES TO MEET WITH THEIR CONGRESSIONAL REPRESENTATIVES. IN 2017, IN LIEU OF HILL DAY, THE LEADERSHIP SUMMIT FOCUSED ON ADVOCACY ISSUES. ADVOCACY ALERTS WERE DISSEMINATED TO SUPPORT CDMRP RESEARCH FUNDING FOR BLADDER CANCER. FORM 990, PAGE 6, PART VI, LINE 11B PRIOR TO FILING, THE FORM 990 IS REVIEWED BY MANAGEMENT AND THE TREASURER OF THE BOARD OF DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 12C ANNUALLY, EACH BOARD MEMBER, OFFICER, AND MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS SIGNS A STATEMENT WHICH AFFIRMS THEY HAVE READ AND ARE COMPLYING WITH BCAN'S CONFLICT OF INTEREST POLICIES. FORM 990, PAGE 6, PART VI, LINE 15A TO DETERMINE APPROPRIATE COMPENSATION FOR BCAN'S EXECUTIVE DIRECTOR, THE OFFICERS ANNUALLY REVIEW THE MOST RECENTLY AVAILABLE NONPROFIT SALARY SURVEYS FOR THE DC METROPOLITAN AREA BEFORE DESIGNATING A SALARY RANGE BASED ON THE EXECUTIVE DIRECTORS SKILLS AND EXPERIENCE. THE PROPOSED COMPENSATION IS SUBJECT TO APPROVAL BY THE BOARD OF DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 15B BCAN'S OFFICERS DO NOT DRAW ANY SALARY, NOR DO THEY GET REIMBURSED FOR TRAVEL TO BOARD MEETINGS. THE APPROPRIATE COMPENSATION FOR BCAN'S OTHER STAFF IS REVIEWED AT LEAST ANNUALLY BY BCAN'S EXECUTIVE DIRECTOR. SHE REVIEWS THE MOST RECENTLY AVAILABLE NONPROFIT SALARY SURVEYS FOR THE DC METROPOLITAN AREA TO DESIGNATE A SALARY RANGE BASED ON STAFF'S SKILLS AND EXPERIENCE. THE PROPOSED COMPENSATION IS SUBJECT TO APPROVAL BY THE BOARD OF DIRECTORS EACH YEAR WHEN THEY APPROVE THE ANNUAL BUDGET. FORM 990, PAGE 6, PART VI, LINE 17 VIRGINIA, WASHINGTON, GEORGIA FORM 990, PAGE 6, PART VI, LINE 19 BLADDER CANCER'S 990 AND DOCUMENTS ARE AVAILABLE TO THE PUBLIC BY REQUEST. THEY ALSO HAVE THE 990 AVAILABLE ON GUIDESTAR.ORG